FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...

Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

Vinay Prasad, named to lead the FDA agency tasked with regulating vaccines and gene therapy, has made controversial comments ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

The US Food and Drug Administration has chosen Dr Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...